Martin, J and Wilcox, M orcid.org/0000-0002-4565-2868 (2016) New and emerging therapies for Clostridium difficile infection. Current Opinion in Infectious Diseases, 29 (6). pp. 546-554. ISSN 0951-7375
Abstract
Purpose of review: Clostridium difficile infection has attained high prominence given its prevalence and impacts on patients and healthcare institutions. Multiple new approaches to the prevention and treatment of C. difficile infection (CDI) are undergoing clinical trials.
Recent findings: Bezlotoxumab is a monoclonal antibody against toxin B that has successfully completed phase III studies, demonstrating a significant reduction in recurrent CDI when given with standard of care antibiotics. Antibiotics under development include cadazolid and ridinilazole, whereas surotomycin has had disappointing phase III results. Multiple live biotherapeutics are being developed, including freeze thawed and encapsulated versions of faecal microbiota transplantation to improve the practicality of treating patients with recurrent CDI. Alternatives to faecal microbiota transplantation, that aim to improve safety, including a microbial suspension, RBX2660, and a complex spore formulation, SER-109, have progressed to phase II studies. A nontoxigenic C. difficile strain has also shown promise to prevent recurrent CDI. In addition, three C. difficile vaccines have progressed to phase II/III clinical trials.
Summary: The diverse approaches to treating and preventing CDI offer substantial promise that new treatment options will soon emerge, particular ones that reduce the risk of recurrences.
Metadata
Item Type: | Article |
---|---|
Authors/Creators: |
|
Copyright, Publisher and Additional Information: | © 2016 Wolters Kluwer Health, Inc. This is an author produced version of a paper published in Current Opinion in Infectious Diseases. Uploaded in accordance with the publisher's self-archiving policy. |
Keywords: | antibiotics, antibodies, live biotherapeutics, vaccines |
Dates: |
|
Institution: | The University of Leeds |
Academic Units: | The University of Leeds > Faculty of Medicine and Health (Leeds) > Institute of Molecular Medicine (LIMM) (Leeds) > Section of Molecular Gastroenterology (Leeds) |
Depositing User: | Symplectic Publications |
Date Deposited: | 23 Aug 2018 11:46 |
Last Modified: | 25 Jun 2023 21:29 |
Status: | Published |
Publisher: | Wolters Kluwer Health, Inc |
Identification Number: | 10.1097/QCO.0000000000000320 |
Open Archives Initiative ID (OAI ID): | oai:eprints.whiterose.ac.uk:134868 |